The debate about the role of the Food and Drug Administration (FDA) in the regulation of laboratory-developed tests (LDTs) has focused attention on the analytical performance of all clinical laboratory testing. This study provides data comparing the performance of LDTs and FDA-approved companion diagnostics (FDA-CDs) in proficiency testing (PT) provided by the College of American Pathologists Molecular Oncology Committee.
R ecent public debate has focused on the regulation of clinical tests. [1] [2] [3] [4] [5] This includes regulatory practices to ensure the highest quality patient care, with the US Food and Drug Administration (FDA) recommending greater oversight of all in vitro testing. In cancer molecular testing, there are several FDA companion diagnostics (FDA-CDs) sold under the designation of in vitro diagnostics (IVDs). There are many more clinical laboratory-developed tests (LDTs) that are designed, validated, and performed in a single laboratory. Proprietary commercial assays can also fall under the LDT umbrella. This study compares analytical validity of FDA-CDs and LDTs using uniform reference materials from the College of American Pathologists Molecular Oncology Committee.
Methods

Sample Definition and Timeframe
The College of American Pathologists is a well-known provider of external proficiency testing (PT) materials that provide a mechanism for laboratories to fulfill the Clinical Laboratory Improvement Amendments requirement for laboratories to assess the analytical validity of clinical assays during initial development and ongoing clinical use. The College of American Pathologists BRAF PT data from the second half of 2011 through the first half of 2015 were included in this comparison of PT responses (14 samples and 8 mailings). For EGFR, data from the first half of 2013 through the first half of 2015 were examined (11 samples and 5 mailings). For KRAS, data from the second half of 2013 through the first half of 2015 were examined (10 samples and 4 mailings). Additional information detailing PT results categorized as "acceptable," specific variants assessed, and select qualitative and quantitative preanalytic considerations are available in the Supplement. Based on the participant responses, the testing methodology was categorized as either FDA-CD or LDT. Laboratories using a kit manufactured by a vendor with FDA approval for that kit after the Meaning This study supports the accuracy and comparable performance of LDTs and FDA-CDs and indicates that the majority of laboratories purchasing in vitro diagnostics for FDA-CDs are in fact using them as LDTs.
FDA approval date were analyzed as FDA-CDs. All other assays were analyzed as LDTs. 
Statistical Analysis
Results
The overall BRAF College of American Pathologists PT acceptable rate was 96.2% with LDTs achieving a 96.6% acceptable rate while FDA-CD results were significantly lo w era t9 3. 0%(P = .002) ( Table 1 ). The main cause of this discrepancy was p.V600K analysis, with LDT acceptable rates at 88.0% while FDA-CDs were 66.1% acceptable (P < .001). For EGFR, LDTs performed slightly less well than the FDA-CDs overall (97.6% acceptability for LDT vs 99.1% for FDA-CDs; P = .03) ( Table 1 ). This discrepancy was driven by the detection of the EGFR p.L861Q mutation (91% for LDTs vs 100% of FDA-CDs; P = .04). For KRAS, there was no significant difference between LDTs and the FDA-CD acceptability rates overall or when the data were broken down by wild-type positions or individual variants. For all 3 surveys, FDA-CD participants reported using off-label preanalytical practices more than 60% of the time. These off-label practices included accepting unapproved specimen and tumor types (Figure) , accepting specimens with lower tumor content than are required for the approved assay, and not quantifying DNA before performing the assay ( Table 2 ). These alterations of the FDA-approved procedure render these tests LDTs.
Discussion
Our primary goal was to compare the accuracy of results between laboratories using FDA-CDs and LDTs. For 1 of 13 variants (BRAF p.V600K), LDTs performed statistically better than FDA-CDs, although 1 of the FDA-CDs is approved only for p.V600E and not other variants at that amino acid or adjacent loci. However, several of these other variants may also respond to BRAF-targeted therapies. For the second variant (EGFR p.L861Q), FDA-CDs performed slightly, but statistically, better than LDTs (Table 1) .
This study also compared FDA-CDs and LDTs for preanalytical factors where specifically mentioned in the FDA-CD protocols, including specimen preparations used for testing, pathologist review, DNA quantification, and tissue dissection. The preanalytic questions highlight the fact that many FDA-CD laboratories conduct practices that are not in accord with their FDA-approved methods. Both FDA-CD and LDT laboratories accept a wide range of specimen preparations, as well as tumor types. Although this flexibility is advantageous for patient care, it is important to recognize that the use of specimens other than formalinfixed paraffin-embedded samples of the specified tumor type for the FDA-CDs is off-label, resulting in reclassification of the assay as an LDT. Abbreviations: FDA, US Food and Drug Administration; LDT, laboratory-developed tests.
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Limitations
There are several limitations of this study. First, each PT response was treated as an individual data point rather than grouping the responses by laboratory. Second, all participants using an assay produced by a vendor with an FDA-CD after the FDA approval date were categorized as FDA-CDs although some laboratories may have been using an alternate unapproved kit or had validated it as an LDT. Third, some laboratories failed to provide responses to all of the PT questions. This resulted in inconsistent numbers of data points for many of the variables, although the discrepancies are small and have minimal impact. Finally, the PT did not include questions about all aspects of the practice of each assay. Therefore, this survey cannot determine if there are additional ways that laboratories are using the FDA-CDs off-label.
Conclusions
We find no differences overall between FDA-CDs and LDTs in assay performance for these 3 analytes, with an average of over 97% accuracy from both types of assays more than the 3 surveys, although a technical limitation of one FDA-CD is noted. This study identified alterations from the FDA-approved procedure in greater than 60% of respondents using FDA-CDs, likely to allow for more clinical practice flexibility. Given the overall comparable performance of FDA-CDs and LDTs, as well as the significant off-label use of FDA-CDs, these data question the distinction between FDA-CDs and LDTs from a regulatory standpoint and note the greater clinically relevant applications of LDTs.
Methods.
Sample Definition and Timeframe.
All CAP proficiency testing (PT) for BRAF from 2011B through 2015A was included in this study. For EGFR, data from 2013A through 2015A were examined. For KRAS, only data from 2013B through 2015A were examined, because the specific option for respondents to indicate the use of the FDA-approved platform was not available until 2013B. For all three analytes, two PTs (A and B) are provided each year. During this time frame, PTs 2011B through 2013B contained only a single specimen. Beginning with 2014A, each mailing contained three specimens. In total, we included data from fourteen samples for BRAF, eleven samples for EGFR, and ten samples for KRAS (ranging from 33% to 100% neoplastic cellularity, the latter in cell lines carrying the variant). Samples for BRAF and EGFR were composed of neoplastic tissue prior to the 2013A survey, and FFPE cell lines thereafter. Samples for KRAS were composed of FFPE cell lines for the entirety of the period of this study.
Method Definition.
Although attempts were made to determine if laboratories using a kit produced by a manufacturer with an FDA-CD were actually using the FDA-CD or a research use only (RUO)
version, too few laboratories responded to enable assignment of laboratories to the proper category. Therefore, for all three surveys, all laboratories using kits purchased from a vendor with an FDA-CD were considered in the FDA cohort for the purpose of this study, acknowledging that some laboratories (in particular for EGFR and KRAS) may have been using the RUO version (and therefore should have been categorized as an LDT).
Data Definition.
Results on CAP PT are considered either good, acceptable, or unacceptable. These terms are defined differently depending upon the type of sample used for the PT. For tissue samples used prior to 2013, a good result (detected or not detected) was one that matched the consensus response, defined as concordance of 80% or greater of respondents. Beginning with the 2013A survey, when cell lines with defined mutations were introduced for the PTs, a good result was defined as the identification of the correct result. Supplementary Table 1 lists the good responses for each of the PTs. The responses, "Does not detect" and "Does not discriminate," were also considered acceptable. However, only laboratories that reported results for a specific variant were included in the subsequent studies on the specific variants while laboratories reporting "does not discriminate variants" or "test not performed" were excluded from further consideration. Therefore, if a laboratory reported "Not detected" for a BRAF p.V600K variant when using an FDA-CD that does not discriminate p.V600K from p.V600E, this was counted in the analysis as unacceptable. For the purposes of this study, all "good" and "acceptable" results are considered "acceptable" and are included in the overall rates of acceptability that are utilized throughout the manuscript.
For the assessment of laboratory practice, select qualitative and quantitative pre-analytic considerations were also surveyed. Of note, not all participants answered all questions; only respondents were considered in our analysis. For the determination of whether or not an FDA-CD laboratory followed the appropriate FDA-approved procedure, the following steps were pulled from the manuals accompanying the kits: specimen preparation (including tissue preparation and type of tumor tested), whether or not a pathologist review is required, the stated minimal neoplastic cellularity for testing, whether or not tissue dissection is performed, whether or not DNA quantification is performed, the method of DNA quantification, and whether or not an interpretive comment was included. For the type of tumor tested, each FDA-CD is limited to a specific tumor type. The PT survey questions only directly interrogated this point on the BRAF survey. For the BRAF assays, an FDA-CD can only test melanomas to be within the FDAapproved procedure. The PT survey questions named specific other tumor types for BRAF, and testing of non-melanoma tumors was considered a formal deviation from the FDA-approved procedure. In the case of neoplastic cellularity, the FDA-approved procedure either specified a minimum tumor content to be used or the minimum tumor content was calculated as twice the minimum detectable variant allele fraction (for bioMerieux THxID® BRAF Test and the therascreen® EGFR RGQ PCR Kit). In the latter therascreen® EGFR assay, there is such a variant-specific range that it was not possible to assign a single minimum tumor cellularity cutoff that a laboratory should accept for testing, rendering an assessment of off-label use of the assay impossible to determine.
